Unveiling the Potential of TIL Therapy in Fighting Cancer
Science News is delving into the world of Tumor-Infiltrating Lymphocyte (TIL) therapy and its revolutionary impact on cancer treatment.
Discover the journey from ancient remedies to modern immunotherapy and the promising future of TIL therapy in combating solid tumors.
Oncologist Steven Rosenberg of the U.S. National Cancer Institute embarked on a quest to harness the body’s immune system for battling cancer back in 1968. Inspired by cases of spontaneous tumor regression linked to immune responses, Rosenberg laid the groundwork for what would eventually become TIL therapy.
The concept of leveraging the immune system to combat cancer traces back to ancient times, with reports of tumors vanishing after infections dating back to ancient Egypt. Fast forward to the 19th century, where experiments by surgeon William Bradley Coley demonstrated the potential of infecting tumors with bacteria to induce tumor shrinkage. Despite initial success, concerns over safety and uncertainty about the mechanism behind the treatment hindered progress in cancer immunotherapy.
Advancements in immunology throughout the 20th century shed light on the complexities of the immune system. Key discoveries, such as the identification of T cells in 1967, paved the way for breakthroughs in cancer treatment. From the introduction of checkpoint inhibitors in 2011 to the approval of CAR T-cell therapy in 2017, the field of immunotherapy witnessed significant milestones in combating various forms of cancer.
TIL therapy represents a new frontier in cancer treatment, particularly for solid tumors like melanoma. While currently approved for advanced melanoma, ongoing research suggests its potential applicability to other solid tumors. The efficacy of TIL therapy raises questions about the variability in treatment outcomes among patients, prompting further exploration into the intricate interplay between the immune system and cancer.
